PDT Partners LLC Trims Stake in Qiagen N.V. $QGEN

Key Points

• PDT Partners LLC reduced its holdings in Qiagen N.V. by 55.7% in the first quarter, bringing their total shares to 45,607 valued at approximately $1.83 million.
• Several institutional investors made moves in Qiagen stock, with SVB Wealth LLC and ANTIPODES PARTNERS Ltd initiating new positions valued at $31,000 and $94,000 respectively.
• Qiagen's earnings per share met analysts' expectations at $0.60 for the quarter, along with a revenue of $533.54 million, indicating a 7.7% increase year over year.

PDT Partners LLC trimmed its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 55.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 45,607 shares of the company's stock after selling 57,436 shares during the quarter. PDT Partners LLC's holdings in Qiagen were worth $1,831,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. SVB Wealth LLC purchased a new position in shares of Qiagen during the first quarter valued at $31,000. ANTIPODES PARTNERS Ltd bought a new position in Qiagen during the 1st quarter worth about $94,000. Tower Research Capital LLC TRC grew its holdings in Qiagen by 770.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after acquiring an additional 2,204 shares in the last quarter. GAMMA Investing LLC increased its position in Qiagen by 93.9% during the 1st quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the period. Finally, Federated Hermes Inc. bought a new stake in shares of Qiagen in the 1st quarter valued at about $150,000. Institutional investors own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

QGEN has been the topic of a number of recent research reports. Wall Street Zen downgraded shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Bank of America upped their target price on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Barclays started coverage on Qiagen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. UBS Group boosted their price target on Qiagen from $48.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, Cowen reaffirmed a "hold" rating on shares of Qiagen in a research report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $49.69.

Qiagen Trading Up 0.9%

Shares of Qiagen stock opened at $46.94 on Wednesday. The firm's 50 day simple moving average is $48.70 and its two-hundred day simple moving average is $44.23. The firm has a market capitalization of $10.43 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.57 and a beta of 0.64. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The business's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.